På grund af den potentielle risiko for bivirkninger hos det diende barn bør der tages stilling til enten at afbryde amningen eller Rebif - behandlingen.
Because of the potential for serious adverse reactions in breast-fed infants, a decision should be made either to discontinue nursing or to discontinue Rebif therapy.